{"id":984555,"date":"2026-07-24T06:40:40","date_gmt":"2026-07-24T10:40:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\/"},"modified":"2026-07-24T06:40:40","modified_gmt":"2026-07-24T10:40:40","slug":"regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\/","title":{"rendered":"$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials \u2013 Investors Notified to Contact BFA Law"},"content":{"rendered":"<h2>\nA securities fraud class action lawsuit has been filed on behalf of Regeneron investors after its stock plummeted almost 10% because Regeneron allegedly misled investors regarding the success of its Phase III Fianlimab-Libtayo clinical trial<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">NEW YORK, July  24, 2026  (GLOBE NEWSWIRE) &#8212; Leading securities law firm\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lG2CFUDxy0LK2jxI75bDILnu9lLrPRxd9SqyMoYhfJXT0v53MP7AZ4PJRLnOpK-9Vjo9oFKBuFbC1iOGcrDNbu44x-bX2uxX5LBtBQN1iBPhX0qPPz6HXaSNrMeyzNfx31RpF_RRXRZnhJZau86YvE6nSxJHJgW7XdOlWKlrCiY=\" rel=\"nofollow\" target=\"_blank\"><strong>Bleichmar Fonti &amp; Auld LLP<\/strong><\/a> announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and certain of the company\u2019s senior executives for securities fraud after significant stock drops resulting from potential violations of the federal securities laws.<\/p>\n<p align=\"left\">If you invested in Regeneron, you are encouraged to obtain additional information by visiting: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kIhmGuAsGttQmpxHJHvq-8UBX99fovNQ3DaYRJXwW4JY6mwRJYaRI8KhXEmwxpObeLC6gpycXk4AW3dZ4R_SCYf5mCuHxLeRUGx2GkP3UCeGHdxt6HGxdvXy1LrC9J8iWjHhRThwTJ7m1hC6Z_BFzN-_pyY51Jn3kX4QnzhdqOMEbZ2JejV8gY0NMdfrhStv2BbZvH5tE8MeIgJfVVMpxw==\" rel=\"nofollow\" target=\"_blank\"><strong>https:\/\/www.bfalaw.com\/cases\/regeneron-class-action-lawsuit<\/strong><\/a>.<\/p>\n<p align=\"left\">\n        <strong>Key Details of the Regeneron ($REGN) Class Action:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Lead Plaintiff Deadline: <\/strong>September 14, 2026<\/li>\n<li>\n          <strong>Alleged Misconduct: <\/strong>Securities fraud alleging that Regeneron misled investors regarding the success of its Phase III Fianlimab-Libtayo clinical trial<\/li>\n<li>\n          <strong>Stock Drop: <\/strong><\/p>\n<ul type=\"circle\">\n<li>April 29, 2026 \u2013 6.2% Stock Drop<\/li>\n<li>May 15, 2026 \u2013 9.8% Stock Drop<\/li>\n<\/ul>\n<\/li>\n<li>\n          <strong>Court: <\/strong>U.S. District Court for the Southern District of New York<\/li>\n<li>\n          <strong>Action: <\/strong>Contact <a href=\"https:\/\/www.bfalaw.com\/cases\/regeneron-class-action-lawsuit\" rel=\"nofollow\" target=\"_blank\">BFA Law<\/a> to discuss your rights<\/li>\n<\/ul>\n<p align=\"left\">Investors have until September 14, 2026, to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Regeneron securities. The class action is pending in the U.S. District Court for the Southern District of New York. It is captioned <em>Cheathem v. Regeneron Pharm., Inc., et al.<\/em>, No. 26-cv-6026.<\/p>\n<p align=\"left\">\n        <strong>Why is Regeneron Being Sued for Securities Fraud?<\/strong>\n      <\/p>\n<p align=\"left\">Regeneron is a pharmaceutical company that discovers, invents, develops, manufactures, tests, and commercializes medicines to treat various disorders.<\/p>\n<p align=\"left\">During the relevant period, Regeneron was investigating Fianlimab, a human monoclonal antibody targeting the LAG-3 immune checkpoint receptor on T-cells. Specifically, Regeneron was testing Fianlimab in combination with Libtayo in a Phase III study to determine whether the drug combination could serve as a first-line treatment for advanced melanoma.<\/p>\n<p align=\"left\">Regeneron told investors that it had \u201ca lot of hope and confidence\u201d that the Phase III trial \u201ccan generate a meaningful differentiation against current standards of care.\u201d Further, despite acknowledging that study results had slowed, Regeneron told investors that this was likely because \u201cthere was a high level of response and those response[s] are very durable\u201d and that the combination drug was a \u201cpotential blockbuster.\u201d<\/p>\n<p align=\"left\">In truth, as alleged, the Phase III Fianlimab-Libtayo study did not achieve statistically significant results.<\/p>\n<p align=\"left\">\n        <strong>Why did Regeneron\u2019s Stock Drop?<\/strong>\n      <\/p>\n<p align=\"left\">On April 29, 2026, before market hours, Regeneron announced the Phase III Fianlimab-Libtayo study \u201cwill now consider all patients enrolled in the study with a minimum follow-up of 6 months.\u201d This expansion of the study parameters indicated the study did not have enough positive results to achieve statistical significance. This news caused the price of Regeneron stock to decline $45.41 per share, or 6.2%, from a closing price of $731.77 per share on April 28, 2026, to $686.36 per share on April 29, 2026.<\/p>\n<p align=\"left\">Then, on May 15, 2026, after market hours, Regeneron published a press release stating that the Phase III Fianlimab-Libtayo \u201cdid not reach statistical significance for the primary endpoint\u201d tested. This news caused the price of Regeneron stock to decline $68.57 per share, or 9.8%, from a closing price of $698.25 per share on May 15, 2026, to $629.68 per share on May 18, 2026.<\/p>\n<p align=\"left\">\n        <strong>Click here for more information: <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kIhmGuAsGttQmpxHJHvq-8UBX99fovNQ3DaYRJXwW4JY6mwRJYaRI8KhXEmwxpObeLC6gpycXk4AW3dZ4R_SCUlanqO20L80BW8nySkKYG1PNxQZCyI6tL-fitGrmhV-hp2_qZLn0Ez0qHgHuR02_8FNvztgRyDOdF5ndgbXzXVZRzlssowuG5IeaqJMdCl80ad-C5n1REXR3NNRgU_Cwg==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>https:\/\/www.bfalaw.com\/cases\/regeneron-class-action-lawsuit<\/strong><br \/>\n        <\/a><br \/>\n        <strong>.<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>What Can You Do?<\/strong>\n      <\/p>\n<p align=\"left\">If you invested in Regeneron, you may have legal options and are encouraged to submit your information to the firm.<\/p>\n<p align=\"left\">All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.<\/p>\n<p align=\"left\">\n        <strong>Submit your information by visiting:<\/strong>\n      <\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kIhmGuAsGttQmpxHJHvq-8UBX99fovNQ3DaYRJXwW4JY6mwRJYaRI8KhXEmwxpObeLC6gpycXk4AW3dZ4R_SCZALcv4FpqFsLw4Vbwa2hX2Vf8G3IEsBKWF9LKQEYzZwiT2rdz556lnlagYk5LV9XIskwqhmkLJ_Ca7_JVNMEK16-qs-lxJjTrCrpldihxWf5IixDwjoAWFiHrm4lCH4XQ==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>https:\/\/www.bfalaw.com\/cases\/regeneron-class-action-lawsuit<\/strong><br \/>\n        <\/a>\n      <\/p>\n<p align=\"left\">Or contact:<br \/>Adam McCall<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4ifbErwcZXmV3Qze03bFor_PvJ2JH9mTnX-Tswz4Qimxn3vSw7Bs6a3RQh1NHZ1Pzj5LfFMHt46Tbm6dFt8nD7aecKC0YI_6yrhT_9F4HZ4=\" rel=\"nofollow\" target=\"_blank\">adam@bfalaw.com<\/a><br \/>212.789.3619<\/p>\n<p align=\"left\">\n        <strong>Why Bleichmar Fonti &amp; Auld LLP?<\/strong>\n      <\/p>\n<p align=\"left\">BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by <em>Chambers USA<\/em>, <em>The Legal 500<\/em>, and <em>ISS SCAS<\/em>, and its attorneys have been named \u201cElite Trial Lawyers\u201d by the <em>National Law Journal<\/em>, \u201cLitigation Stars\u201d by <em>Benchmark Litigation<\/em>, among the top \u201c500 Leading Plaintiff Financial Lawyers\u201d by <em>Lawdragon<\/em>, \u201cTitans of the Plaintiffs\u2019 Bar\u201d by <em>Law360<\/em> and \u201cSuperLawyers\u201d by Thomson Reuters.<\/p>\n<p align=\"left\">Most recently,\u00a0<em>The Legal 500\u00a0<\/em>awarded BFA the most client satisfaction accolades of any plaintiff\u2019s securities litigation law firm, with clients noting: \u201c[t]here is no better service provider in the practice area,\u201d \u201c[t]he interest of the client is always front and center,\u201d and \u201c[t]here isn\u2019t a better firm in this space.\u201d\u00a0 One testimonial described the firm as \u201cnimble and entrepreneurial,\u201d with a \u201crelentless focus on adding value for clients.\u201d<\/p>\n<p align=\"left\">Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.\u2019s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.<\/p>\n<p align=\"left\">For more information about BFA and its attorneys, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kIhmGuAsGttQmpxHJHvq-8UBX99fovNQ3DaYRJXwW4LNXaw7wCxBlHGdvfEM9Q82SrRM5dr8erA6kXtpr7pQgu-g4rMdENnvnSuPXgl3LMA=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.bfalaw.com<\/a>.<\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kIhmGuAsGttQmpxHJHvq-8UBX99fovNQ3DaYRJXwW4JY6mwRJYaRI8KhXEmwxpObeLC6gpycXk4AW3dZ4R_SCTGvCk4tBR_YjscNa2TjY3slcu2s4H7umGpA2tbTLBGskjTYVST8B296Z2m1dBnha-mgSLDdTW8DiuzIO1MFP8lQkzaTjh6wym-d7YyUNQ3Y8v66b7QUujfam5MPWeSoog==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>https:\/\/www.bfalaw.com\/cases\/regeneron-class-action-lawsuit<\/strong><br \/>\n        <\/a>\n      <\/p>\n<p align=\"left\">\n        <em>Attorney advertising. Past results do not guarantee future outcomes.<\/em>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2Njc4MSM3NzE5MDA1IzIyOTA5OTU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzFiOTk0OTQtMWM2My00YzdjLWI4NjctNmVhYWU3MzFlMWEyLTEzMDI1NDUtMjAyNi0wNy0yNC1lbg==\/tiny\/Bleichmar-Fonti-Auld.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>A securities fraud class action lawsuit has been filed on behalf of Regeneron investors after its stock plummeted almost 10% because Regeneron allegedly misled investors regarding the success of its Phase III Fianlimab-Libtayo clinical trial NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) &#8212; Leading securities law firm\u00a0Bleichmar Fonti &amp; Auld LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and certain of the company\u2019s senior executives for securities fraud after significant stock drops resulting from potential violations of the federal securities laws. If you invested in Regeneron, you are encouraged to obtain additional information by visiting: https:\/\/www.bfalaw.com\/cases\/regeneron-class-action-lawsuit. Key Details of the Regeneron ($REGN) Class Action: Lead Plaintiff Deadline: September 14, 2026 Alleged Misconduct: Securities &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials \u2013 Investors Notified to Contact BFA Law&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-984555","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials \u2013 Investors Notified to Contact BFA Law - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials \u2013 Investors Notified to Contact BFA Law - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"A securities fraud class action lawsuit has been filed on behalf of Regeneron investors after its stock plummeted almost 10% because Regeneron allegedly misled investors regarding the success of its Phase III Fianlimab-Libtayo clinical trial NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) &#8212; Leading securities law firm\u00a0Bleichmar Fonti &amp; Auld LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and certain of the company\u2019s senior executives for securities fraud after significant stock drops resulting from potential violations of the federal securities laws. If you invested in Regeneron, you are encouraged to obtain additional information by visiting: https:\/\/www.bfalaw.com\/cases\/regeneron-class-action-lawsuit. Key Details of the Regeneron ($REGN) Class Action: Lead Plaintiff Deadline: September 14, 2026 Alleged Misconduct: Securities &hellip; Continue reading &quot;$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials \u2013 Investors Notified to Contact BFA Law&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-24T10:40:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2Njc4MSM3NzE5MDA1IzIyOTA5OTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials \u2013 Investors Notified to Contact BFA Law\",\"datePublished\":\"2026-07-24T10:40:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\\\/\"},\"wordCount\":843,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2Njc4MSM3NzE5MDA1IzIyOTA5OTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\\\/\",\"name\":\"$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials \u2013 Investors Notified to Contact BFA Law - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2Njc4MSM3NzE5MDA1IzIyOTA5OTU=\",\"datePublished\":\"2026-07-24T10:40:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2Njc4MSM3NzE5MDA1IzIyOTA5OTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2Njc4MSM3NzE5MDA1IzIyOTA5OTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials \u2013 Investors Notified to Contact BFA Law\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials \u2013 Investors Notified to Contact BFA Law - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\/","og_locale":"en_US","og_type":"article","og_title":"$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials \u2013 Investors Notified to Contact BFA Law - Market Newsdesk","og_description":"A securities fraud class action lawsuit has been filed on behalf of Regeneron investors after its stock plummeted almost 10% because Regeneron allegedly misled investors regarding the success of its Phase III Fianlimab-Libtayo clinical trial NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) &#8212; Leading securities law firm\u00a0Bleichmar Fonti &amp; Auld LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and certain of the company\u2019s senior executives for securities fraud after significant stock drops resulting from potential violations of the federal securities laws. If you invested in Regeneron, you are encouraged to obtain additional information by visiting: https:\/\/www.bfalaw.com\/cases\/regeneron-class-action-lawsuit. Key Details of the Regeneron ($REGN) Class Action: Lead Plaintiff Deadline: September 14, 2026 Alleged Misconduct: Securities &hellip; Continue reading \"$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials \u2013 Investors Notified to Contact BFA Law\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-24T10:40:40+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2Njc4MSM3NzE5MDA1IzIyOTA5OTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials \u2013 Investors Notified to Contact BFA Law","datePublished":"2026-07-24T10:40:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\/"},"wordCount":843,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2Njc4MSM3NzE5MDA1IzIyOTA5OTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\/","name":"$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials \u2013 Investors Notified to Contact BFA Law - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2Njc4MSM3NzE5MDA1IzIyOTA5OTU=","datePublished":"2026-07-24T10:40:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2Njc4MSM3NzE5MDA1IzIyOTA5OTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2Njc4MSM3NzE5MDA1IzIyOTA5OTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-fraud-notification-regeneron-sued-for-fraud-over-misrepresentations-about-its-clinical-trials-investors-notified-to-contact-bfa-law\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials \u2013 Investors Notified to Contact BFA Law"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/984555","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=984555"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/984555\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=984555"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=984555"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=984555"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}